Skip to content
Study details
Enrolling now

Spironolactone Trial to Improve Pregnancy-Associated Hypertension

Massachusetts General Hospital
NCT IDNCT07041281ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

204

Study length

about 3.4 years

Ages

18+

Sex

Female only

Locations

3 sites in MA, PA

What this study is about

Researchers are testing whether spironolactone, a medication that blocks the mineralocorticoid receptor, can improve blood pressure and heart health in women who have had gestational hypertension or preeclampsia. The trial will last for 1233 days (about three years) after delivery.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo tablet to match spironolactone
  • 2.Take spironolactone 25 mg orally once daily

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

diuretic (Potassium-sparing diuretic; aldosterone antagonist)

Drug routes

oral (Oral Tablet), oral

Endpoints

Primary: Mean 24-hour ambulatory diastolic blood pressure

Secondary: Mean 24-hour ambulatory systolic blood pressure, Mean diurnal ambulatory diastolic blood pressure, Mean diurnal ambulatory systolic blood pressure, Mean nocturnal ambulatory diastolic blood pressure, Mean nocturnal ambulatory systolic blood pressure, Measured diastolic blood pressure, Measured systolic blood pressure, N-terminal pro-B-type natriuretic peptide

Body systems

Reproductive Health, Cardiology / Heart